August 23, 2023

What's driving turbo cancers and autoimmune flare-ups?

The complete article was published on the Alliance for Natural Health website on August 23rd 2023.

Summary of the key messages:

Immune refocusing is the key to immune escape and collateral non-SARS-CoV-2 disease

  • Immune refocusing (IR) to more conserved, immune subdominant spike-associated domainselicits subneutralizing antibodies that promote large-scale immune escape and mature into IgG4s that react with self- or altered self epitopes on the surface of healthy or pathologically transformed host cells.
  • Pathogenic IgG4 Abs link immune escape and vaccine breakthrough infections (VBTIs) toincreased incidence of autoimmune diseases and early-onset cancers.
  • Immune pathology (incl. cancer) results from IR-enabling VBTI or IR-enabling vaccination (mRNA vaccination).

High IgG4 Ab titers combined with exposure to highly infectious variants link immune selection pressure on viral virulence to generalized immune suppression

  • High titers of IgG4 Abs no longer enable immune refocusing upon exposure to highly infectious SARS-CoV-2 variants and prevent production of (polyreactive) non-neutralizing antibodies (Abs).
  • When these Abs collectively decline below an optimal threshold, the virus will likely break through their virulence-inhibiting capacity and unleash a major wave of severe Covid-19 disease.

Immune pathology is triggered byimmune refocusing and therefore caused by vaccine breakthrough infections(VBTI) or mRNA vaccination

  • The likelihood for Covid-19 vaccinees to contract immune pathology or cancer, or to suffer from resurgence of chronic infection following VBTI with Omicron descendants in highly C-19 vaccinated populations is not primarily determined by genetic predisposition, environmental factors or demographic characteristics but by the amount of time elapsed since the first occurrence of immune refocusing.
  • The type of pathology and the type of organ/ tissue affected depends on the specificity of the pathogenic anti-spike IgG4 Abs.

There is a calm just now; the calm before the storm

  • Enhanced rate of cancers, autoimmune disorders or exacerbations of other, chronic infections in the context of low Covid-19 morbidity and mortality rates are currently the only and last clinical alert left to warn highly C-19 vaccinated countries about a dramatic and imminent viral immune escape event.
  • However, as the origin of the above-described side effects and excess deaths in highly C-19 vaccinated populations is currently not debatable and as their nature is not considered by scientists and health authorities to reflect dangerous immune escape, I keep shouting that society in highly Covid-19 vaccinated countries will be caught off guard!

High IgG4 Abs are correlates of immune escape

  • Measuring IgG4 Ab titers in the blood of asymptomatic C-19 vaccinees, possibly complemented by measuring infectious shedding in mucosal swabs (via SARS-CoV-2 Ag test or RT-PCR), could be a good proxy for investigating irreversible immune escape (i.e., following IR-enabling VBTI).
  • I postulate that a high prevalence of high titers of IgG4 Abs in a highly C-19 vaccinated population is to be considered a poor prognostic sign for the outcome of this SARS-CoV-2 (immune escape) pandemic.

Who’s at risk? How can people at risk protect themselves?

download article as a PDF 

Support our work
Subscribe to our Substack Newsletter

Geert Vanden Bossche received his DVM from the University of Ghent, Belgium, and his PhD degree in Virology from the University of Hohenheim, Germany. He held adjunct faculty appointments at universities in Belgium and Germany. After his career in Academia, Geert joined several vaccine companies (GSK Biologicals, Novartis Vaccines, Solvay Biologicals) to serve various roles in vaccine R&D as well as in late vaccine development.

Geert then moved on to join the Bill & Melinda Gates Foundation’s Global Health Discovery team in Seattle (USA) as Senior Program Officer; he then worked with the Global Alliance for Vaccines and Immunization (GAVI) in Geneva as Senior Ebola Program Manager. At GAVI he tracked efforts to develop an Ebola vaccine. He also represented GAVI in fora with other partners, including WHO, to review progress on the fight against Ebola and to build plans for global pandemic preparedness.

Back in 2015, Geert scrutinized and questioned the safety of the Ebola vaccine that was used in ring vaccination trials conducted by WHO in Guinea. His critical scientific analysis and report on the data published by WHO in the Lancet in 2015 was sent to all international health and regulatory authorities involved in the Ebola vaccination program. After working for GAVI, Geert joined the German Center for Infection Research in Cologne as Head of the Vaccine Development Office. He is at present primarily serving as a Biotech / Vaccine consultant while also conducting his own research on Natural Killer cell-based vaccines.


Recent Posts
June 17, 2024

Will there be another newly emerging SARS-CoV-2 variant that outcompetes KP.3 or is this the end of the virus's 'gentle' survival strategy?

June 17, 2024

The Endgame

June 7, 2024

It's going to be a new CoV, not the avian flu virus

Voices for Science and solidarity, © 2023